Claims
- 1. A compound of the formula:
- 2. The compound of claim 1, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.
- 3. The compound of claim 1, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C12-C26 fatty acid occurring naturally in humans.
- 4. The compound of claim 1, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C14-C24 fatty acid occurring naturally in humans.
- 5. The compound of claim 1, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 6. The compound of claim 5 wherein the pharmaceutical agent is an anticancer drug.
- 7. The compound of claim 5 wherein the pharmaceutical agent is an antiviral drug.
- 8. The compound of claim 5 wherein the pharmaceutical agent is an antipsychotic drug.
- 9. The compound of claim 5 wherein the pharmaceutical agent is paclitaxel.
- 9. The compound of claim 5 wherein the pharmaceutical agent is paclitaxel.
- 10. The compound of claim 5 wherein the pharmaceutical agent is flavopiridol.
- 11. A compound of the formula:
- 12. The compound of claim 11, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.
- 13. The compound of claim 11, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C12-C26 fatty acid occurring naturally in humans.
- 14. The compound of claim 11, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C14-C24 fatty acid occurring naturally in humans.
- 15. The compound of claim 11, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 16. The compound of claim 11, wherein R′ is selected from H, Na+, K+, Li+, and NH4+.
- 17. The compound of claim 15 wherein the pharmaceutical agent is an anticancer drug.
- 18. The compound of claim 15 wherein the pharmaceutical agent is an antiviral drug.
- 19. The compound of claim 15 wherein the pharmaceutical agent is an antipsychotic drug.
- 20. The compound of claim 15 wherein the pharmaceutical agent is paclitaxel.
- 21. The compound of claim 15 wherein the pharmaceutical agent is flavopiridol.
- 22. The compound of claim 15 wherein the pharmaceutical agent is adefovir.
- 23. A compound of the formula:
- 24. The compound of claim 23, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C12-C26 fatty acid occurring naturally in humans.
- 25. The compound of claim 23, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C14-C24 fatty acid occurring naturally in humans.
- 26. The compound of claim 23, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapenataenoic acid, docosahexaenoic acid, and nervonic acid.
- 27. The compound of claim 26 wherein the pharmaceutical agent is an anticancer drug.
- 28. The compound of claim 26 wherein the pharmaceutical agent is an antiviral drug.
- 29. The compound of claim 26 wherein the pharmaceutical agent is an antipsychotic drug.
- 30. The compound of claim 26 wherein the pharmaceutical agent is adefovir.
- 31. A compound of the formula:
- 32. The compound of claim 31, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.
- 33. The compound of claim 31, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C12-C26 fatty acid occurring naturally in humans.
- 34. The compound of claim 31, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C14-C24 fatty acid occurring naturally in humans.
- 35. The compound of claim 31, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 36. The compound of claim 35 wherein the pharmaceutical agent is an anticancer drug.
- 37. The compound of claim 35 wherein the pharmaceutical agent is an antiviral drug.
- 38. The compound of claim 35 wherein the pharmaceutical agent is an antipsychotic drug.
- 39. A compound of the formula:
- 40. The compound of claim 39, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.
- 41. The compound of claim 39, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C12-C26 fatty acid occurring naturally in humans.
- 42. The compound of claim 39, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a C14-C24 fatty acid occurring naturally in humans.
- 43. The compound of claim 39, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 44. The compound of claim 43 wherein the pharmaceutical agent is an anticancer drug.
- 45. The compound of claim 43 wherein the pharmaceutical agent is an antiviral drug.
- 46. The compound of claim 43 wherein the pharmaceutical agent is an antipsychotic drug.
- 47. The compound of claim 43 wherein the pharmaceutical agent is paclitaxel.
- 48. The compound of claim 43 wherein the pharmaceutical agent is flavopiridol.
- 49. A compound of the formula:
- 50. The compound of claim 49, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 51. A compound of the formula:
- 52. The compound of claim 51, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 53. The compound of claim 51 wherein T is —SCH3 or pyrazole.
- 54. A pharmaceutical preparation comprising a compound of the formula
- 55. The pharmaceutical preparation of claim 54, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 56. The pharmaceutical preparation of claim 55 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 57. The pharmaceutical preparation of claim 55 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 58. A pharmaceutical preparation comprising a compound of the formula:
- 59. The pharmaceutical preparation of claim 58, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 60. The pharmaceutical preparation of claim 58, wherein R′ is H or Na+.
- 61. The pharmaceutical preparation of claim 59 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 62. The pharmaceutical preparation of claim 59 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 63. A pharmaceutical preparation comprising a compound of the formula:
- 64. The pharmaceutical preparation of claim 63, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 65. The pharmaceutical preparation of claim 64 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 66. The pharmaceutical preparation of claim 64 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 67. A pharmaceutical preparation comprising a compound of the formula:
- 68. The pharmaceutical preparation of claim 67, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 69. The pharmaceutical preparation of claim 68 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 70. A pharmaceutical preparation comprising a compound of the formula:
- 71. The pharmaceutical preparation of claim 70, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 72. The pharmaceutical preparation of claim 71 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 73. The pharmaceutical preparation of claim 71 wherein the pharmaceutical agent is paclitaxel or flavopiridol.
- 74. A method of making a compound of the formula:
- 75. The method of claim 74, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 76. The method of claim 75 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 77. The method of claim 75 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 78. A method of making a compound of the formula:
- 79. The method of claim 78, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 80. The method of claim 79 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 81. The method of claim 79 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 82. A method of making a compound of the formula:
- 83. The method of claim 82, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 84. The method of claim 83 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 85. The method of claim 83 wherein the pharmaceutical agent is adefovir.
- 86. A method of making a compound of the formula:
- 87. The method of claim 86, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 88. The method of claim 87 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 89. A method of treating a disorder comprising administering to a subject in need of such treatment a pharmaceutical preparation comprising a compound of the formula:
- 90. The method of claim 89, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 91. The method of claim 90 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 92. The method of claim 90 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 93. The method of claim 90 wherein the disorder is a mammalian cell proliferation disorder.
- 94. The method of claim 93 wherein the pharmaceutical agent is paclitaxel.
- 95. The method of claim 93 wherein the pharmaceutical agent is flavopiridol.
- 96. The method of claim 90 wherein the disorder is a mammalian viral disorder.
- 97. The method of claim 90 wherein the disorder is a mammalian psychiatric disorder.
- 98. A method of treating a disorder comprising administering to a subject in need of such treatment a pharmaceutical preparation comprising a compound of the formula:
- 99. The method of claim 98, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 100. The method of claim 99 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 101. The method of claim 99 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 102. The method of claim 99 wherein the disorder is a mammalian cell proliferation disorder.
- 103. The method of claim 102 wherein the pharmaceutical agent is paclitaxel.
- 104. The method of claim 102 wherein the pharmaceutical agent is flavopiridol.
- 105. The method of claim 99 wherein the disorder is a mammalian viral disorder.
- 106. The method of claim 105 wherein the pharmaceutical agent is adefovir.
- 107. The method of claim 99 wherein the disorder is a mammalian psychiatric disorder.
- 108. A method of treating a disorder comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of the formula:
- 109. The method of claim 108, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 110. The method of claim 109 wherein the pharmaceutical agent is ananticancer drug, an antiviral drug, or an antipsychotic drug.
- 111. The method of claim 109 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 112. The method of claim 109 wherein the disorder is a mammalian cell proliferation disorder.
- 113. The method of claim 109 wherein the disorder is a mammalian viral disorder.
- 114. The method of claim 109 wherein the disorder is a mammalian psychiatric disorder.
- 115. A method of treating a disorder comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of the formula:
- 116. The method of claim 115, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 117. The method of claim 116 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 118. The method of claim 116 wherein the disorder is a mammalian cell proliferation disorder.
- 119. The method of claim 115 wherein the disorder is a mammalian viral disorder.
- 120. The method of claim 115 wherein the disorder is a mammalian psychiatric disorder.
- 121. A method of treating a disorder comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a compound of the formula:
- 122. The method of claim 121, wherein the fatty amine RNH2 has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.
- 123. The method of claim 122 wherein the pharmaceutical agent is an anticancer drug, an antiviral drug, or an antipsychotic drug.
- 124. The method of claim 122 wherein the pharmaceutical agent is paclitaxel, flavopiridol, or adefovir.
- 125. The method of claim 122 wherein the disorder is a mammalian cell proliferation disorder.
- 126. The method of claim 125 wherein the pharmaceutical agent is paclitaxel.
- 127. The method of claim 125 wherein the pharmaceutical agent is flavopiridol.
- 128. The method of claim 125 wherein the disorder is a mammalian viral disorder.
- 129. The method of claim 125 wherein the disorder is a mammalian psychiatric disorder.
RELATED APPLICATION
[0001] This application claims priority under 35 U.S.C. §119 (e) from U.S. provisional patent application Serial No. 60/278,552, filed on Mar. 23, 2001, entitled Fatty Amine Drug Conjugates. The contents of the provisional application are expressly incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60278552 |
Mar 2001 |
US |